biostudies-literatureUnknown2(2)Alvarez-Buylla AMerck Sharp and Dohme<h4>Objectives</h4>To evaluate the <i>in vitro</i> activity of ceftolozane/tazobactam and other commonly used antipseudomonal antibiotics against geographically spread <i>Pseudomonas aeruginosa</i> isolates in the UK using disc susceptibility testing.<h4>Methods</h4>The <i>in vitro</i> activity of ceftolozane/tazobactam and nine other commonly used antipseudomonal antibiotics was evaluated. Isolates were collected between January 2015 and April 2018. Susceptibility results were interpreted using EUCAST 2018 criteria.<h4>Results</h4>Overall, 1326 clinical isolates from 14 centres in the UK were tested. The majority of the isolates were collected from non-cystic fibrosis (non-CF) patients (<i>n </i>=<i> </i>1123, 85.0%). In addition, 199 cystic fibrosis (CF) isolates were collected from 10 cJAC-antimicrobial resistancedlaa024https://www.ebi.ac.uk/biostudies/studies/S-EPMC8209992biostudies-literatureMulticentre study of the <i>in vitro</i> activity of ceftolozane/tazobactam and other commonly used antibiotics against <i>Pseudomonas aeruginosa</i> isolates from patients in the UK.PMC8209992INVICTUS study groupAlvarez-Buylla AAllen MBennett SBetts DMonahan IPlanche TfalseMulticentre study of the <i>in vitro</i> activity of ceftolozane/tazobactam and other commonly used antibiotics against <i>Pseudomonas aeruginosa</i> isolates from patients in the UK.<h4>Objectives</h4>To evaluate the <i>in vitro</i> activity of ceftolozane/tazobactam and other commonly used antipseudomonal antibiotics against geographically spread <i>Pseudomonas aeruginosa</i> isolates in the UK using disc susceptibility testing.<h4>Methods</h4>The <i>in vitro</i> activity of ceftolozane/tazobactam and nine other commonly used antipseudomonal antibiotics was evaluated. Isolates were collected between January 2015 and April 2018. Susceptibility results were interpreted using EUCAST 2018 criteria.<h4>Results</h4>Overall, 1326 clinical isolates from 14 centres in the UK were tested. The majority of the isolates were collected from non-cystic fibrosis (non-CF) patients (<i>n </i>=<i> </i>1123, 85.0%). In addition, 199 cystic fibrosis (CF) isolates were collected from 10 c2020-01-01T00:00:00Z2020 Jun2025-04-18T19:15:17.015Z2022-02-10T18:01:12.236ZS-EPMC82099923422298810.1093/jacamr/dlaa024